Long-Acting Opioid Analgesics for Acute Pain: Pharmacokinetic Evidence Reviewed
Long-acting injectable (LAI) opioid formulations mitigate the harm profiles and management challenges associated with providing effective analgesia for animals. A single dose of a long-acting opioid analgesic can provide up to 72 h of clinically relevant pain management. Yet, few of these new drugs...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Veterinary Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2306-7381/10/6/372 |
| _version_ | 1797592368510140416 |
|---|---|
| author | Betty M. Tyler Michael Guarnieri |
| author_facet | Betty M. Tyler Michael Guarnieri |
| author_sort | Betty M. Tyler |
| collection | DOAJ |
| description | Long-acting injectable (LAI) opioid formulations mitigate the harm profiles and management challenges associated with providing effective analgesia for animals. A single dose of a long-acting opioid analgesic can provide up to 72 h of clinically relevant pain management. Yet, few of these new drugs have been translated to products for veterinary clinics. Regulatory pathways allow accelerated drug approvals for generic and biosimilar drugs. These pathways depend on rigorous evidence for drug safety and pharmacokinetic evidence demonstrating bioequivalence between the new and the legacy drug. This report reviews the animal PK data associated with lipid and polymer-bound buprenorphine LAI formulations. Buprenorphine is a widely used veterinary opioid analgesic. Because of its safety profile and regulatory status, buprenorphine is more accessible than morphine, methadone, and fentanyl. This review of PK studies coupled with the well-established safety profile of buprenorphine suggests that the accelerated approval pathways may be available for this new family of LAI veterinary pharmaceuticals. |
| first_indexed | 2024-03-11T01:51:10Z |
| format | Article |
| id | doaj.art-8aa69f3d36ba4b01a26a4d06d5a904dc |
| institution | Directory Open Access Journal |
| issn | 2306-7381 |
| language | English |
| last_indexed | 2024-03-11T01:51:10Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Veterinary Sciences |
| spelling | doaj.art-8aa69f3d36ba4b01a26a4d06d5a904dc2023-11-18T12:59:58ZengMDPI AGVeterinary Sciences2306-73812023-05-0110637210.3390/vetsci10060372Long-Acting Opioid Analgesics for Acute Pain: Pharmacokinetic Evidence ReviewedBetty M. Tyler0Michael Guarnieri1Department of Neurosurgery, Johns Hopkins University, 1550 Orleans Street, 1550 Orleans St. CRB II, Baltimore, MD 21287, USADepartment of Neurosurgery, Johns Hopkins University, 1550 Orleans Street, 1550 Orleans St. CRB II, Baltimore, MD 21287, USALong-acting injectable (LAI) opioid formulations mitigate the harm profiles and management challenges associated with providing effective analgesia for animals. A single dose of a long-acting opioid analgesic can provide up to 72 h of clinically relevant pain management. Yet, few of these new drugs have been translated to products for veterinary clinics. Regulatory pathways allow accelerated drug approvals for generic and biosimilar drugs. These pathways depend on rigorous evidence for drug safety and pharmacokinetic evidence demonstrating bioequivalence between the new and the legacy drug. This report reviews the animal PK data associated with lipid and polymer-bound buprenorphine LAI formulations. Buprenorphine is a widely used veterinary opioid analgesic. Because of its safety profile and regulatory status, buprenorphine is more accessible than morphine, methadone, and fentanyl. This review of PK studies coupled with the well-established safety profile of buprenorphine suggests that the accelerated approval pathways may be available for this new family of LAI veterinary pharmaceuticals.https://www.mdpi.com/2306-7381/10/6/372analgesiabuprenorphineharm reductionlong actingpharmacokineticextended release |
| spellingShingle | Betty M. Tyler Michael Guarnieri Long-Acting Opioid Analgesics for Acute Pain: Pharmacokinetic Evidence Reviewed Veterinary Sciences analgesia buprenorphine harm reduction long acting pharmacokinetic extended release |
| title | Long-Acting Opioid Analgesics for Acute Pain: Pharmacokinetic Evidence Reviewed |
| title_full | Long-Acting Opioid Analgesics for Acute Pain: Pharmacokinetic Evidence Reviewed |
| title_fullStr | Long-Acting Opioid Analgesics for Acute Pain: Pharmacokinetic Evidence Reviewed |
| title_full_unstemmed | Long-Acting Opioid Analgesics for Acute Pain: Pharmacokinetic Evidence Reviewed |
| title_short | Long-Acting Opioid Analgesics for Acute Pain: Pharmacokinetic Evidence Reviewed |
| title_sort | long acting opioid analgesics for acute pain pharmacokinetic evidence reviewed |
| topic | analgesia buprenorphine harm reduction long acting pharmacokinetic extended release |
| url | https://www.mdpi.com/2306-7381/10/6/372 |
| work_keys_str_mv | AT bettymtyler longactingopioidanalgesicsforacutepainpharmacokineticevidencereviewed AT michaelguarnieri longactingopioidanalgesicsforacutepainpharmacokineticevidencereviewed |